Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 investigator-initiated trial to determine safety, efficacy, and key translational data of CNTY-101 in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis

X
Trial Profile

A phase 1/2 investigator-initiated trial to determine safety, efficacy, and key translational data of CNTY-101 in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CNTY-101 (Primary)
  • Indications Diffuse scleroderma; Lupus nephritis; Myositis; Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARAMEL Trial
  • Most Recent Events

    • 27 Jan 2025 New trial record
    • 21 Jan 2025 According to a Century Therapeutics media release, the CARAMEL trial with Century is intended to commence in mid-2025 following CTA approval.
    • 21 Jan 2025 According to a Century Therapeutics media release, company has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas Mackensen of CNTY-101 in patients with B-cell mediated autoimmune diseases. The IIT, which is sponsored by the Friedrich-Alexander University Erlangen-Nurnberg, , represents the first evaluation by the internationally recognized Schett/Mackensen group.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top